NEW YORK – Personalis and Tempus AI said Monday that they have expanded their partnership to jointly commercialize Personalis' NeXT Personal Dx minimal residual disease (MRD) assay to reach biopharmaceutical customers.
The companies initially inked the deal last year for the diagnostics market only. Under the terms of that deal, Tempus served as Personalis' exclusive commercial diagnostic partner for the tumor-informed, whole-genome liquid biopsy assay. Tempus integrated NeXT Personal Dx into its testing menu and markets it to oncologists. Under the expanded agreement, Tempus will now be able to offer the test to pharmaceutical and biotech customers seeking to combine MRD testing with other Tempus offerings in their studies.
"While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," Personalis CEO Chris Hall said in a statement.